+关注
Really_8279
暂无个人介绍
IP属地：福建
65
关注
0
粉丝
10
主题
0
勋章
主贴
热门
Really_8279
2023-12-28
怎么套利都没说
@美股解毒师:两个重磅生物医药收购，有多少套利机会？
Really_8279
2023-11-17
具体是什么不坦诚
抱歉，原内容已删除
Really_8279
2020-06-10
吊
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3545134460208818","uuid":"3545134460208818","gmtCreate":1582040438242,"gmtModify":1582176443530,"name":"Really_8279","pinyin":"really8279really8279","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":65,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":10,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":67,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"93.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.05","exceedPercentage":"60.26%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"福建","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":7,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":256843904508136,"gmtCreate":1703739528468,"gmtModify":1703739529856,"author":{"id":"3545134460208818","authorId":"3545134460208818","name":"Really_8279","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545134460208818","authorIdStr":"3545134460208818"},"themes":[],"htmlText":"怎么套利都没说","listText":"怎么套利都没说","text":"怎么套利都没说","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/256843904508136","repostId":"256497605423120","repostType":1,"repost":{"id":256497605423120,"gmtCreate":1703649009580,"gmtModify":1703649088231,"author":{"id":"3440721572920950","authorId":"3440721572920950","name":"美股解毒师","avatar":"https://static.tigerbbs.com/bbf0f514b8e5abb92266789b89f6e1e6","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3440721572920950","authorIdStr":"3440721572920950"},"themes":[],"title":"两个重磅生物医药收购，有多少套利机会？","htmlText":"施贵宝收购RayzeBio <a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 将以每股62.50美元的现金收购仅仅上市三个月的 <a href=\"https://laohu8.com/S/RYZB\">$RayzeBio, Inc.(RYZB)$</a> ，总股权价值约为41亿美元，预计BMY将通过融资新债务来完成这笔收购交易，预计将于2024年上半年完成。该交易预计将对BMY 2024年的摊薄后EPS造成约0.13美元的不利影响。Bristol Myers Squibb将获得RayzeBio基于α核素的差异化放射性药物技术平台和多款在研创新产品，包括RYZ101、RYZ801等创新靶向核药，极大丰富了其肿瘤产品管线，进一步领先肿瘤学特许经营权增加放射性药物平台RYZ101主要项目处于第3阶段开发，用于治疗胃肠胰神经内分泌肿瘤，并且早期开发用于治疗小细胞肺癌和潜在的其他肿瘤类型。RayzeBio成立于2020年，是一家处于临床阶段的创新放射性疗法（RPT）公司。短短4年间，该公司不仅成功发展为一家综合性核药公司，还在今年9月中旬顺利登陆纳斯达克，以3.11亿美元的募资总额跻身2023年全球创新药领域IPO前列上市后RayzeBio的表现也相当强势，3个月从每股18元增长至收购前的30.57美元，涨幅70%。目前该公司市值36亿美元，还有月20%的溢价。阿斯利康将收购亘喜生物 <a href=\"https://laohu8.com/S/AZN\">$阿斯利康(AZN)$</a> 周二宣布已正式达成协议，以最多12亿美元收购中国 <a href=\"https://laohu8.com/S/GRCL\">$亘喜生物(GRCL)$</a> ，这是前者扩展细胞疗法业务的努力的一部分。该交易还包括10亿美元的现金，每股最高0.30美元的不可更","listText":"施贵宝收购RayzeBio <a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 将以每股62.50美元的现金收购仅仅上市三个月的 <a href=\"https://laohu8.com/S/RYZB\">$RayzeBio, Inc.(RYZB)$</a> ，总股权价值约为41亿美元，预计BMY将通过融资新债务来完成这笔收购交易，预计将于2024年上半年完成。该交易预计将对BMY 2024年的摊薄后EPS造成约0.13美元的不利影响。Bristol Myers Squibb将获得RayzeBio基于α核素的差异化放射性药物技术平台和多款在研创新产品，包括RYZ101、RYZ801等创新靶向核药，极大丰富了其肿瘤产品管线，进一步领先肿瘤学特许经营权增加放射性药物平台RYZ101主要项目处于第3阶段开发，用于治疗胃肠胰神经内分泌肿瘤，并且早期开发用于治疗小细胞肺癌和潜在的其他肿瘤类型。RayzeBio成立于2020年，是一家处于临床阶段的创新放射性疗法（RPT）公司。短短4年间，该公司不仅成功发展为一家综合性核药公司，还在今年9月中旬顺利登陆纳斯达克，以3.11亿美元的募资总额跻身2023年全球创新药领域IPO前列上市后RayzeBio的表现也相当强势，3个月从每股18元增长至收购前的30.57美元，涨幅70%。目前该公司市值36亿美元，还有月20%的溢价。阿斯利康将收购亘喜生物 <a href=\"https://laohu8.com/S/AZN\">$阿斯利康(AZN)$</a> 周二宣布已正式达成协议，以最多12亿美元收购中国 <a href=\"https://laohu8.com/S/GRCL\">$亘喜生物(GRCL)$</a> ，这是前者扩展细胞疗法业务的努力的一部分。该交易还包括10亿美元的现金，每股最高0.30美元的不可更","text":"施贵宝收购RayzeBio $施贵宝(BMY)$ 将以每股62.50美元的现金收购仅仅上市三个月的 $RayzeBio, Inc.(RYZB)$ ，总股权价值约为41亿美元，预计BMY将通过融资新债务来完成这笔收购交易，预计将于2024年上半年完成。该交易预计将对BMY 2024年的摊薄后EPS造成约0.13美元的不利影响。Bristol Myers Squibb将获得RayzeBio基于α核素的差异化放射性药物技术平台和多款在研创新产品，包括RYZ101、RYZ801等创新靶向核药，极大丰富了其肿瘤产品管线，进一步领先肿瘤学特许经营权增加放射性药物平台RYZ101主要项目处于第3阶段开发，用于治疗胃肠胰神经内分泌肿瘤，并且早期开发用于治疗小细胞肺癌和潜在的其他肿瘤类型。RayzeBio成立于2020年，是一家处于临床阶段的创新放射性疗法（RPT）公司。短短4年间，该公司不仅成功发展为一家综合性核药公司，还在今年9月中旬顺利登陆纳斯达克，以3.11亿美元的募资总额跻身2023年全球创新药领域IPO前列上市后RayzeBio的表现也相当强势，3个月从每股18元增长至收购前的30.57美元，涨幅70%。目前该公司市值36亿美元，还有月20%的溢价。阿斯利康将收购亘喜生物 $阿斯利康(AZN)$ 周二宣布已正式达成协议，以最多12亿美元收购中国 $亘喜生物(GRCL)$ ，这是前者扩展细胞疗法业务的努力的一部分。该交易还包括10亿美元的现金，每股最高0.30美元的不可更","images":[{"img":"https://static.tigerbbs.com/1ad7be5ac6c36ed7f3dea59c6b24a640","width":"1080","height":"589"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/256497605423120","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":242661469548768,"gmtCreate":1700264741038,"gmtModify":1700274495925,"author":{"id":"3545134460208818","authorId":"3545134460208818","name":"Really_8279","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545134460208818","authorIdStr":"3545134460208818"},"themes":[],"htmlText":"具体是什么不坦诚 ","listText":"具体是什么不坦诚 ","text":"具体是什么不坦诚","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/242661469548768","repostId":"2384939343","repostType":2,"isVote":1,"tweetType":1,"viewCount":1423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956404279,"gmtCreate":1591752330991,"gmtModify":1704196755556,"author":{"id":"3545134460208818","authorId":"3545134460208818","name":"Really_8279","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545134460208818","authorIdStr":"3545134460208818"},"themes":[],"htmlText":"吊","listText":"吊","text":"吊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956404279","repostId":"2042048344","repostType":2,"isVote":1,"tweetType":1,"viewCount":2498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":256843904508136,"gmtCreate":1703739528468,"gmtModify":1703739529856,"author":{"id":"3545134460208818","authorId":"3545134460208818","name":"Really_8279","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545134460208818","authorIdStr":"3545134460208818"},"themes":[],"htmlText":"怎么套利都没说","listText":"怎么套利都没说","text":"怎么套利都没说","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/256843904508136","repostId":"256497605423120","repostType":1,"repost":{"id":256497605423120,"gmtCreate":1703649009580,"gmtModify":1703649088231,"author":{"id":"3440721572920950","authorId":"3440721572920950","name":"美股解毒师","avatar":"https://static.tigerbbs.com/bbf0f514b8e5abb92266789b89f6e1e6","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3440721572920950","authorIdStr":"3440721572920950"},"themes":[],"title":"两个重磅生物医药收购，有多少套利机会？","htmlText":"施贵宝收购RayzeBio <a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 将以每股62.50美元的现金收购仅仅上市三个月的 <a href=\"https://laohu8.com/S/RYZB\">$RayzeBio, Inc.(RYZB)$</a> ，总股权价值约为41亿美元，预计BMY将通过融资新债务来完成这笔收购交易，预计将于2024年上半年完成。该交易预计将对BMY 2024年的摊薄后EPS造成约0.13美元的不利影响。Bristol Myers Squibb将获得RayzeBio基于α核素的差异化放射性药物技术平台和多款在研创新产品，包括RYZ101、RYZ801等创新靶向核药，极大丰富了其肿瘤产品管线，进一步领先肿瘤学特许经营权增加放射性药物平台RYZ101主要项目处于第3阶段开发，用于治疗胃肠胰神经内分泌肿瘤，并且早期开发用于治疗小细胞肺癌和潜在的其他肿瘤类型。RayzeBio成立于2020年，是一家处于临床阶段的创新放射性疗法（RPT）公司。短短4年间，该公司不仅成功发展为一家综合性核药公司，还在今年9月中旬顺利登陆纳斯达克，以3.11亿美元的募资总额跻身2023年全球创新药领域IPO前列上市后RayzeBio的表现也相当强势，3个月从每股18元增长至收购前的30.57美元，涨幅70%。目前该公司市值36亿美元，还有月20%的溢价。阿斯利康将收购亘喜生物 <a href=\"https://laohu8.com/S/AZN\">$阿斯利康(AZN)$</a> 周二宣布已正式达成协议，以最多12亿美元收购中国 <a href=\"https://laohu8.com/S/GRCL\">$亘喜生物(GRCL)$</a> ，这是前者扩展细胞疗法业务的努力的一部分。该交易还包括10亿美元的现金，每股最高0.30美元的不可更","listText":"施贵宝收购RayzeBio <a href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$</a> 将以每股62.50美元的现金收购仅仅上市三个月的 <a href=\"https://laohu8.com/S/RYZB\">$RayzeBio, Inc.(RYZB)$</a> ，总股权价值约为41亿美元，预计BMY将通过融资新债务来完成这笔收购交易，预计将于2024年上半年完成。该交易预计将对BMY 2024年的摊薄后EPS造成约0.13美元的不利影响。Bristol Myers Squibb将获得RayzeBio基于α核素的差异化放射性药物技术平台和多款在研创新产品，包括RYZ101、RYZ801等创新靶向核药，极大丰富了其肿瘤产品管线，进一步领先肿瘤学特许经营权增加放射性药物平台RYZ101主要项目处于第3阶段开发，用于治疗胃肠胰神经内分泌肿瘤，并且早期开发用于治疗小细胞肺癌和潜在的其他肿瘤类型。RayzeBio成立于2020年，是一家处于临床阶段的创新放射性疗法（RPT）公司。短短4年间，该公司不仅成功发展为一家综合性核药公司，还在今年9月中旬顺利登陆纳斯达克，以3.11亿美元的募资总额跻身2023年全球创新药领域IPO前列上市后RayzeBio的表现也相当强势，3个月从每股18元增长至收购前的30.57美元，涨幅70%。目前该公司市值36亿美元，还有月20%的溢价。阿斯利康将收购亘喜生物 <a href=\"https://laohu8.com/S/AZN\">$阿斯利康(AZN)$</a> 周二宣布已正式达成协议，以最多12亿美元收购中国 <a href=\"https://laohu8.com/S/GRCL\">$亘喜生物(GRCL)$</a> ，这是前者扩展细胞疗法业务的努力的一部分。该交易还包括10亿美元的现金，每股最高0.30美元的不可更","text":"施贵宝收购RayzeBio $施贵宝(BMY)$ 将以每股62.50美元的现金收购仅仅上市三个月的 $RayzeBio, Inc.(RYZB)$ ，总股权价值约为41亿美元，预计BMY将通过融资新债务来完成这笔收购交易，预计将于2024年上半年完成。该交易预计将对BMY 2024年的摊薄后EPS造成约0.13美元的不利影响。Bristol Myers Squibb将获得RayzeBio基于α核素的差异化放射性药物技术平台和多款在研创新产品，包括RYZ101、RYZ801等创新靶向核药，极大丰富了其肿瘤产品管线，进一步领先肿瘤学特许经营权增加放射性药物平台RYZ101主要项目处于第3阶段开发，用于治疗胃肠胰神经内分泌肿瘤，并且早期开发用于治疗小细胞肺癌和潜在的其他肿瘤类型。RayzeBio成立于2020年，是一家处于临床阶段的创新放射性疗法（RPT）公司。短短4年间，该公司不仅成功发展为一家综合性核药公司，还在今年9月中旬顺利登陆纳斯达克，以3.11亿美元的募资总额跻身2023年全球创新药领域IPO前列上市后RayzeBio的表现也相当强势，3个月从每股18元增长至收购前的30.57美元，涨幅70%。目前该公司市值36亿美元，还有月20%的溢价。阿斯利康将收购亘喜生物 $阿斯利康(AZN)$ 周二宣布已正式达成协议，以最多12亿美元收购中国 $亘喜生物(GRCL)$ ，这是前者扩展细胞疗法业务的努力的一部分。该交易还包括10亿美元的现金，每股最高0.30美元的不可更","images":[{"img":"https://static.tigerbbs.com/1ad7be5ac6c36ed7f3dea59c6b24a640","width":"1080","height":"589"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/256497605423120","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":242661469548768,"gmtCreate":1700264741038,"gmtModify":1700274495925,"author":{"id":"3545134460208818","authorId":"3545134460208818","name":"Really_8279","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545134460208818","authorIdStr":"3545134460208818"},"themes":[],"htmlText":"具体是什么不坦诚 ","listText":"具体是什么不坦诚 ","text":"具体是什么不坦诚","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/242661469548768","repostId":"2384939343","repostType":2,"isVote":1,"tweetType":1,"viewCount":1423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956404279,"gmtCreate":1591752330991,"gmtModify":1704196755556,"author":{"id":"3545134460208818","authorId":"3545134460208818","name":"Really_8279","avatar":"https://static.tigerbbs.com/19aa889dc092815201d8d6e067aa6133","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545134460208818","authorIdStr":"3545134460208818"},"themes":[],"htmlText":"吊","listText":"吊","text":"吊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956404279","repostId":"2042048344","repostType":2,"isVote":1,"tweetType":1,"viewCount":2498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
